MedPath

STUDY OF INTRAVENOUS SILDENAFIL ON PULMONARY HYPERTENSION IN PATIENTS UNDERGOING MITRAL VALVE REPLACEMENT SURGERY

Phase 2
Conditions
Health Condition 1: O- Medical and SurgicalHealth Condition 2: I050- Rheumatic mitral stenosis
Registration Number
CTRI/2024/01/061106
Lead Sponsor
Department of anaesthesiology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Planned to undergo mitral valve replacement surgery

2.Patient willing to give informed consent.

3.Weight between 40-70kg

4.Patient belonging to ASA grade 2 and 3

5.Ejection fraction more than 40%

Exclusion Criteria

1.Severe hypotension on the day or before the day of surgery(SBP <80 mmhg)..

2.Patients with coronary heart disease or those taking nitrates

3.Endocrine,metabolic,neurologic and psychotic disorder

4. tricuspid stenosis

5.Severe hepatic(ALT or AST >3 times the upper limit of normal) or renal dysfunction(creatinine clearance <30 ml/hr), Peptic ulcer or bleeding

6.Ongoing or prior malignancy.

7.History of allergy to study drug

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br/ ><br>1.Mean Pulmonary artery pressure <br/ ><br>2.Pulmonary vascular resistance <br/ ><br>3.Heart rate <br/ ><br>4. Systolic diastolic and mean arterial pressureTimepoint: 1.Cardiac index <br/ ><br>2.Central venous pressure <br/ ><br>3.Side effects if any
Secondary Outcome Measures
NameTimeMethod
1.Cardiac index <br/ ><br>2.Central venous pressure <br/ ><br>3.Side effects if anyTimepoint: T1- before induction <br/ ><br>T2- After induction <br/ ><br>T3- after off pump <br/ ><br>T4- After 6 hours of surgery <br/ ><br>T5- After 12 hours of surgery <br/ ><br>T6-After 24 hours of surgery
© Copyright 2025. All Rights Reserved by MedPath